Cost–Effectiveness of Angiotensin-converting Enzyme Inhibitors in Nondiabetic Advanced Renal Disease

Charles Christian Adarkwah; Afschin Gandjour


Expert Rev Pharmacoeconomics Outcomes Res. 2011;11(2):215-223. 

In This Article

Expert Commentary

For patients with nondiabetic proteinuric advanced renal disease covered by the SHI, treatment with an ACE inhibitor is highly cost effective. It is still unclear whether a societal perspective leads to larger or smaller savings than an SHI perspective. On the one hand, ACE inhibitor treatment avoids productivity loss due to renal failure and copayments for the treatment of renal failure. On the other hand, drug copayments lead to additional costs. Moreover, the transferability of the conclusion of this study to other countries is limited given differences in costs, clinical management (e.g., treatment of ESRD) and epidemiology.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.